-
1.发明授权公开(公告)号：US11330806B2
公开(公告)日：2022-05-17
申请号：US15740974
申请日：2015-07-02
Inventor： Jinsong Li , Yuxuan Wu , Cuiqing Zhong , Qi Yin , Zhenfei Xie , Meizhu Bai
IPC: A01K67/00 , A01K67/027 , C12N15/85 , C12N15/113 , C12N15/877 , C12N5/0735 , C12N15/873
Abstract: The present invention relates to an AG-haESCs in which H19 DMR and IG-DMR are knocked out, a method for preparing the AG-haESCs, and use of the AG-haESCs in constructing a genetically modified semi-cloned animal and a library of a genetically modified semi-cloned animal. The AG-haESCs is capable of obtaining characteristics resembling a round spermatid, and upon injection into an oocyte, a viable SC mouse is stably obtained. The present invention is capable of being effectively used in multi-gene genetic manipulation, advancing the acquisition of animals with multiple genetic modifications.
-
公开(公告)号：US20240392304A1
公开(公告)日：2024-11-28
申请号：US18695345
申请日：2022-09-26
Inventor： Siqi LI , Yifeng XU , Chuxiao LIU , Lingling CHEN
IPC: C12N15/67
Abstract: The present invention relates to the field of biomedicine, in particular, to an improved circular RNA and a preparation method thereof, wherein the improved circular RNA has high generation efficiency and reduced immunogenicity. The present invention also relates to a vector for the preparation of the improved circular RNA, and the use of the improved circular RNA.
-
公开(公告)号：US20240383913A1
公开(公告)日：2024-11-21
申请号：US18689921
申请日：2022-09-07
Applicant: CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES , SHANGHAITECH UNIVERSITY
Inventor： Sheng Wang , Jianjun Cheng , Luyu Fan , Huan Wang , Zhangcheng Chen , Jing Yu , Wenwen Duan , Dongmei Cao
IPC: C07D495/16 , A61K31/4985 , A61K31/55 , A61P25/24
Abstract: Disclosed in the present invention are a thiophene ring compound, a preparation method therefor and an application thereof. The structure of the thiophene ring compound of the present invention is as shown in formula I. The compound of the present invention has good affinity and agonistic activity against at least one of a dopamine receptor and a 5-hydroxytryptamine receptor.
-
公开(公告)号：US20240042026A1
公开(公告)日：2024-02-08
申请号：US18009713
申请日：2021-06-11
Inventor： CHENQI XU , QIUPING ZHOU , WEI WU , XING HE , HE SUN
IPC: A61K39/00 , C07K14/725 , C07K14/705 , C07K16/28 , C07K16/32 , A61P35/00 , C12N15/86
CPC classification number: A61K39/4631 , C07K14/7051 , C07K14/70521 , C07K16/2803 , C07K16/32 , A61K39/4611 , A61K39/464468 , A61K39/464412 , A61P35/00 , C12N15/86 , C07K2319/03 , C12N2740/15043
Abstract: A chimeric antigen receptor, includes an extracellular domain, a transmembrane domain, and an intracellular domain, which are connected in sequence, where the extracellular domain includes an antigen recognition region and a hinge region, and one end of the intracellular domain which is connected to the transmembrane domain is connected to a CD3ε intracellular region. The chimeric antigen receptor can further improve the treatment effect of B-cell leukemia lymphoma, and reduce inflammatory cytokines generated from macrophage mononuclear cell activation by down-regulating cytokines, so that cytokine storm can be prevented in an early stage, and the risk of neurotoxicity can be reduced. The treatment effect of mesothelin high-expression solid tumors is further improved in mesothelin-positive tumor treatment, and the prevention of cytokine storm and the reduced risk of neurotoxicity can be realized at an early stage.
-
公开(公告)号：US20240002855A1
公开(公告)日：2024-01-04
申请号：US18254616
申请日：2021-11-26
Inventor： JingYi Hui , JinZhu Wang , Hong Zhu
IPC: C12N15/113 , C07K14/82 , C07K19/00 , A61P35/00
CPC classification number: C12N15/1135 , C07K14/82 , C07K19/00 , A61P35/00 , C12N2320/33 , C12N2310/321
Abstract: Provided are a nucleic acid molecule binding to an YB-1 protein and an application thereof in diagnosis, prevention and treatment of cancers. The nucleic acid molecule comprises a sequence selected from the group consisting of: (1) a nucleic acid sequence shown in N1N2N3N4AN5CN6N7N8 (SEQ ID NO: 1), wherein N1 is C, G, U, or none, N2 is A, G, U, or none, N3 is C, G, U, or none, N4 is C, G, U, or none, N5 is C or U, and each of N6, N7 and N8 is independently C, G, U, or none; and (2) a complementary sequence of (1).
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20230043161A1
公开(公告)日：2023-02-09
申请号：US17789378
申请日：2020-08-28
IPC: A61K38/57 , A61K35/545 , A61P1/16 , G01N33/50
Abstract: The present invention provides an application of CST1 in prevention and/or treatment of liver immune dysregulation diseases. Specifically, the present invention provides an application of a CST1 gene, or a protein thereof, or a promoter thereof for preparing a composition or a preparation. The composition or the preparation is used for prevention and/or treatment of liver immune dysregulation diseases.
-
公开(公告)号：US20220347226A1
公开(公告)日：2022-11-03
申请号：US17761445
申请日：2020-09-17
Inventor： Yi Zeng , Daisong Wang
Abstract: Provided herein are endocrine progenitor cells and organoids derived from adult islets in vitro, as well as methods for making and using the same. The compositions are useful for treating or preventing diabetes, other diseases or disorders characterized by impaired islet function, and symptoms thereof.
-
公开(公告)号：US20220017599A1
公开(公告)日：2022-01-20
申请号：US17294527
申请日：2019-11-19
Inventor： Jianfeng Chen , Changdong Lin
IPC: C07K14/705 , C12N15/85 , C12N15/90 , C12N5/0783
Abstract: A composition and method for regulating the migration of immune cells. The method for regulating the migration of immune cells comprises the step of strengthening or weakening the interaction between Hsp90 and α4 integrin in immune cells. Also provided is an immune cell capable of strengthening or weakening the interaction between Hsp90 and α4 integrin and a pharmaceutical composition thereof. The present method and pharmaceutical composition may be used to treat pathogen infections and autoimmune diseases or to kill tumor cells.
-
公开(公告)号：US20210340494A1
公开(公告)日：2021-11-04
申请号：US17281161
申请日：2019-08-14
Inventor： Lijian Hui , Ludi Zhang , Kun Zhang
IPC: C12N5/071 , A61K35/407 , A61P1/16
Abstract: Provided are a method for expanding a hepatocyte in vitro and an application thereof. A culture system is provided for reprogramming a human hepatocyte into a proliferating intermediate-state cell between a mature hepatocyte and a liver progenitor cell. The liver repopulation ability of the system was verified in animals. The method does not require the introduction of an exogenous gene into a hepatocyte, and the expansion of the hepatocyte can be realized by conventional culture. The obtained hepatocyte can be passaged, and can be cultured to maturation to obtain a functional mature human hepatocyte.
-
10.发明公开公开(公告)号：US20230365925A1
公开(公告)日：2023-11-16
申请号：US18248443
申请日：2020-10-09
Inventor： Xin Cheng , Xiaogang Deng , Jiaying Wu , Tianlong Fu
IPC: C12N5/073
CPC classification number: C12N5/0603 , C12N2506/02 , C12N2501/11 , C12N2501/727
Abstract: Provided are a method for inducing differentiated cells into pluripotent endoderm stem cells and an application thereof. Specifically, provided is a method for inducing human differentiated cells to differentiate into induced pluripotent endoderm stem cells (smEnSC), comprising the step of: (a) culturing differentiated cells in a culture system under a first culture condition to obtain induced pluripotent endoderm stem cells (smEnSC), the culture system comprising EGF, A83-01, and CHIR99021. Functional induced pluripotent endodermal stem cells have a high differentiation rate and purity.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.029 seconds)
